Cyrano Therapeutics to Participate in 2025 BIO International Convention

Topline data from Phase 2 FLAVOR trial expected in second half of 2025; advancing therapeutic innovation in post-viral smell loss

DELRAY BEACH, Fla., June 11, 2025 /PRNewswire/ -- Cyrano Therapeutics, Inc., a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss, today announced its participation in the 2025 BIO International Convention, to be held June 16–19, 2025, at the Boston Convention & Exhibition Center.

Cyrano's executive leadership team will be onsite to engage with potential partners, investors, and fellow innovators in regenerative medicine and drug delivery. Discussions will focus on the company's lead program, CYR-064, a novel intranasal spray in development for post-viral hyposmia, and its unique approach to penetrating the olfactory region—a major hurdle in treating sensory dysfunction. CYR-064 is currently being evaluated in the Phase 2 FLAVOR trial, with topline data expected in the second half of 2025.

About Cyrano Therapeutics
Cyrano Therapeutics is a private, venture-backed clinical stage regenerative medicine company. Since our foundation, we have been working diligently to develop therapies for people struggling with the loss of smell and taste. To learn more, please visit cyranotherapeutics.com.

Contact
Tiberend Strategic Advisors, Inc.
Jonathan Nugent (investors)
+1-205-566-3026
[email protected] 

Eric Reiss (media)
[email protected] 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cyrano-therapeutics-to-participate-in-2025-bio-international-convention-302478277.html

SOURCE Cyrano Therapeutics